Patritumab Deruxtecan in Untreated Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Final Results from Part A of the Window-of-Opportunity SOLTI TOT-HER3 Pre-Operative Study.
暂无分享，去创建一个
B. González-Farré | D. Sellami | J. M. Ferrero-Cafiero | J. Cejalvo | P. Parul | T. Pascual | L. Paré | M. Espinosa-Bravo | S. Pernas | E. Ciruelos | G. Villacampa | C. Falato | J. Guerra | O. Martínez-Sáez | E. Sanfeliu | A. Prat | A. Santhanagopal | M. M. Vila | Y. Izarzugaza | A. Luna | S. Esker | P. Tolosa | M. Oliveira | M. Vidal | M. Arumí | P. Fan | F. J. Salvador-Bofill | J. Cruz